Melanoma and non-melanoma skin cancers in hairy cell leukaemia: A Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center Journal Article

   

Authors:	Watts, J. M.; Kishtagari, A.; Hsu, M.; Lacouture, M. E.; Postow, M. A.; Park, J. H.; Stein, E. M.; Teruya-Feldstein, J.; Abdel-Wahab, O.; Devlin, S. M.; Tallman, M. S.
Article Title:	Melanoma and non-melanoma skin cancers in hairy cell leukaemia: A Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center
Abstract:	Few studies have examined melanoma and non-melanoma skin cancer (NMSC) incidence rates after a diagnosis of hairy cell leukaemia (HCL). We assessed 267 HCL patients treated at Memorial Sloan Kettering Cancer Center (MSKCC) and Surveillance, Epidemiology and End Results (SEER) data for melanoma and NMSC incidence rates after HCL. Incidence data from MSKCC patients demonstrated a 10-year combined melanoma and NMSC skin cancer rate of 11·3%, melanoma 4·4% and NMSC 6·9%. Molecular analysis of skin cancers from MSKCC patients revealed activating RAS mutations in 3/9 patients, including one patient with melanoma. Of 4750 SEER patients with HCL, 55 (1·2%) had a subsequent diagnosis of melanoma. Standardized incidence ratios (SIRs) did not show that melanoma was more common in HCL patients versus the general population (SIR 1·3, 95% CI 0·78-2·03). Analysis of SEER HCL patients diagnosed before and after 1990 (approximately before and after purine analogue therapy was introduced) showed no evidence of an increased incidence after 1990. A better understanding of any potential association between HCL and skin cancer is highly relevant given ongoing trials using BRAF inhibitors, such as vemurafenib, for relapsed HCL, as RAS-mutant skin cancers could be paradoxically activated in these patients. © 2015 John Wiley & Sons Ltd.
Keywords:	adult; aged; gene mutation; major clinical study; cancer recurrence; alpha interferon; cancer incidence; genetic analysis; melanoma; skin cancer; cohort analysis; gene frequency; cancer center; population research; oncogene k ras; epidemiology; pentostatin; cladribine; hairy cell leukemia; disease surveillance; ras mutations; clinical trial (topic); oncogene n ras; vemurafenib; secondary cancers; epidemiological data; non melanoma skin cancer; very elderly; human; male; female; priority journal; article; hairy cell leukaemia
Journal Title:	British Journal of Haematology
Volume:	171
Issue:	1
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2015-10-01
Start Page:	84
End Page:	90
Language:	English
DOI:	10.1111/bjh.13528
PROVIDER:	scopus
PUBMED:	26115047
PMCID:	PMC4766022
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84941735945&partnerID=40&md5=2e311f8e35c3955710a6edef3cd9d4e2
Notes:	Export Date: 2 October 2015 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/81151